BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37526379)

  • 1. Drivers of de novo Serine/Glycine synthesis in acute leukemia.
    Verstraete P; De Keersmaecker K; Kampen KR
    FEBS Lett; 2023 Sep; 597(17):2145-2146. PubMed ID: 37526379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.
    Bjelosevic S; Gruber E; Newbold A; Shembrey C; Devlin JR; Hogg SJ; Kats L; Todorovski I; Fan Z; Abrehart TC; Pomilio G; Wei A; Gregory GP; Vervoort SJ; Brown KK; Johnstone RW
    Cancer Discov; 2021 Jun; 11(6):1582-1599. PubMed ID: 33436370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia.
    Zhang Y; Newsom KJ; Zhang M; Kelley JS; Starostik P
    Mol Cancer Res; 2022 Feb; 20(2):293-304. PubMed ID: 34635505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
    Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
    Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer.
    Heylen E; Verstraete P; Van Aerschot L; Geeraerts SL; Venken T; Timcheva K; Nittner D; Verbeeck J; Royaert J; Gijbels M; Uyttebroeck A; Segers H; Lambrechts D; Cools J; De Keersmaecker K; Kampen KR
    Br J Cancer; 2023 May; 128(10):1862-1878. PubMed ID: 36932191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting RIPK1 in AML cells carrying FLT3-ITD.
    Hillert LK; Bettermann-Bethge K; Nimmagadda SC; Fischer T; Naumann M; Lavrik IN
    Int J Cancer; 2019 Sep; 145(6):1558-1569. PubMed ID: 30828789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
    Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
    Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
    Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
    Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
    Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
    Wang YG; Liu XH; Liang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.
    Gao Y; Jia M; Mao Y; Cai H; Jiang X; Cao X; Zhou D; Li J
    Am J Clin Pathol; 2022 May; 157(5):691-700. PubMed ID: 34664628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.